about
CD4+CD25+ regulatory cells contribute to the regulation of colonic Th2 granulomatous pathology caused by schistosome infectionFluorescent imaging of antigen released by a skin-invading helminth reveals differential uptake and activation profiles by antigen presenting cellsBlood flukes exploit Peyer's Patch lymphoid tissue to facilitate transmission from the mammalian hostShort-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis.Enhanced pro-inflammatory cytokine responses following Toll-like-receptor ligation in Schistosoma haematobium-infected schoolchildren from rural GabonA murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasisMultiple helminth infection of the skin causes lymphocyte hypo-responsiveness mediated by Th2 conditioning of dermal myeloid cells.Human filarial Wolbachia lipopeptide directly activates human neutrophils in vitroCirculating CD14brightCD16+ 'intermediate' monocytes exhibit enhanced parasite pattern recognition in human helminth infection.The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models.Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis.Wolbachia endosymbionts induce neutrophil extracellular trap formation in human onchocerciasis.Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis.Wolbachia-induced neutrophil activation in a mouse model of ocular onchocerciasis (river blindness).A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection.T helper cell type 2 responsiveness predicts future susceptibility to gastrointestinal nematodes in humans.Gastrointestinal nematode infection is associated with variation in innate immune responsiveness.Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis.Intensity of intestinal infection with multiple worm species is related to regulatory cytokine output and immune hyporesponsiveness.Evaluation of in vitro culture systems for the maintenance of microfilariae and infective larvae of Loa loa.The Mannose Receptor (CD206) is an important pattern recognition receptor (PRR) in the detection of the infective stage of the helminth Schistosoma mansoni and modulates IFNγ production.Validation of ultrasound bioimaging to predict worm burden and treatment efficacy in preclinical filariasis drug screening models.Interleukin-4 activated macrophages mediate immunity to filarial helminth infection by sustaining CCR3-dependent eosinophilia.Cytokine response profiles predict species-specific infection patterns in human GI nematodesTh2 Cytokines Are Associated with Reduced Worm Burdens in a Human Intestinal Helminth InfectionSchistosome infection is associated with enhanced whole-blood IL-10 secretion in response to cercarial excretory/secretory productsIndustrial scale high-throughput screening delivers multiple fast acting macrofilaricidesAWZ1066S, a highly specific anti- drug candidate for a short-course treatment of filariasisShort-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection modelsDiscovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activityMouse models of Loa loaBoron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic FilariasisComparison of immune responses to Loa loa stage-specific antigen extracts in Loa loa-exposed BALB/c mice upon clearance of infectionNovel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis?In vitro maintenance of Mansonella perstans microfilariae and its relevance for drug screeningImplementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocolDiscovery of short-course antiwolbachial quinazolines for elimination of filarial worm infectionsShort-course quinazoline drug treatments are effective in the Litomosoides sigmodontis and Brugia pahangi jird modelsDataset on in vitro maintenance of Mansonella perstans microfilariae and drug testingPreclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis
P50
Q27306067-D88667A7-7B7E-49A3-BD1E-994014A88721Q27306771-547B44C1-A5C1-4B04-9DEF-1C4ADA890317Q27339697-F2CEB171-2039-4820-AF54-636BE9EA793DQ30377066-B575A595-99BA-4757-BA68-C4FE7BE02B0CQ34023491-6838EE87-7154-4A33-9050-D0B66437A75CQ34416898-B7A418F6-9E50-4E9B-910F-876B0455F629Q34693180-14353CB4-09B3-49F9-961E-FDEBE87A8EECQ34805265-2ADCC8CB-1A9B-4112-ABB0-C9A94043E441Q35156780-D8CEC2E0-0EE3-47C5-8BCC-C9C2288521D4Q36599857-8DA9E92F-2047-492F-8656-7602527462CFQ36708214-41032897-9597-4B94-AAC9-F7C1EA6E483FQ37345869-93AC3F86-B818-48E8-A2E8-7D02F20D23FEQ37372289-D173ED1F-4AF5-41A8-8083-07BC60172501Q37522724-0A6D6C19-66C6-43A4-AF39-CB7C6737A3E2Q39538761-9DBAD42C-404B-4F10-A661-B509350E61A7Q40473905-FEB3B53E-66F7-4717-AA0D-A35B45505E33Q43673355-735AB288-7B52-4364-BE34-49E6D887B352Q44288385-A9FEC76F-0942-4BF1-98BE-26E76E02C6D8Q46798744-91970481-EFCA-40F8-A0CD-64A214A76238Q53069763-04FE8BD8-542E-4909-B77E-FD9AA9124071Q53090616-474803C0-F1D7-4982-B541-C6E15DD60964Q54236651-454E2D93-C2EE-4CC3-BFFD-435C8285D6A7Q55333225-ACC0C8D7-E551-4D55-9C4A-B36D70C1E7ACQ58227438-B2CAEE1A-6704-4182-9436-B30A6DF40115Q58227442-DCE1E57E-B128-47B5-8C18-9CA3D7D746DFQ58371266-E3D79641-2E2E-4EF9-93F0-D946074CAC6EQ60922213-44DE77C7-71EE-4688-BD45-FBBCCF66148AQ61450807-66276957-020A-4AA6-9FF0-3163481F3848Q61815663-60BAB81F-6F2E-4642-A14E-9236356143E7Q64091742-42C7416F-8887-481B-9007-9EE606EAD7F1Q64104195-D7044347-3D55-42D3-B5E0-894E4ABD9949Q64268314-1DBF244E-E23F-4F29-896A-4946D75E3BFEQ89599924-DEC04540-EAEC-4ECA-94AA-67DC51C53566Q89999742-57D92F52-C8E0-4D5F-952C-57064949BDFBQ90456299-33093B3A-D15D-4E9D-9C3D-1CD1481FC575Q91695904-9814B32D-8FA6-4B6E-A007-556DDB673D1BQ91863242-49F517DC-7D6A-4313-8985-67816AEEE5E5Q92209251-A4683F67-8195-499F-8C9D-33D4DF99553DQ92314781-37EE837E-B82A-4E1D-877C-0CCC50FA41F4Q92340277-8D425A32-053B-458E-950B-3752208EB1FC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joseph D Turner
@ast
Joseph D Turner
@en
Joseph D Turner
@es
Joseph D Turner
@nl
type
label
Joseph D Turner
@ast
Joseph D Turner
@en
Joseph D Turner
@es
Joseph D Turner
@nl
prefLabel
Joseph D Turner
@ast
Joseph D Turner
@en
Joseph D Turner
@es
Joseph D Turner
@nl
P106
P21
P31
P496
0000-0002-2185-5476